Approved for use through 07/31/2012, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

## Complete if Known

Application Number	10/581,106
Filing Date	May 31, 2006
First Named Inventor	Judith A. Fox
Art Unit	1642

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Examiner Name Unassigned Attorney Docket Number GC822-US Sheet 1 of 19

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (F known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US- 4,458,066	07/03/1984	Caruthers et al.	
	A2	<sup>US-</sup> 4,522,811	06/11/1985	Eppstein et al.	
	A3	<sup>US-</sup> 4,675,187	06/23/1987	Konishi et al.	
	A4	<sup>US-</sup> 4,711,845	12/08/1987	Gelfand et al.	
	A5	<sup>US-</sup> 4,975,278	12/04/1990	Senter et al.	
	A6	<sup>US-</sup> 5,711,944	01/27/1998	Gilbert et al.	
	A7	<sup>US-</sup> 5,766,883	06/16/1998	Ballance et al.	
	A8	US- 5,773,435	06/30/1998	Kadow et al.	
	A9	US- 5,843,440	12/01/1998	Pouletty et al.	
	A10	<sup>US-</sup> 60/388,387	12/24/2003	Schellenberger	
	A11	<sup>US-</sup> 2002/0142359	10/03/2002	Copley, et al.	
	A12	US- 10/170,729	03/13/2003	Edwards et al.	
	A13	<sup>US-</sup> 10/022,073	04/10/2003	Chen et al.	
	A14	<sup>US-</sup> 09/954,385	05/29/2003	Aehle et al.	
	A15	US- 10/170,387	06/05/2003	Murray	
	A16	us- 10/022,097	08/07/2003	Schellenberger	
	A17	<sup>US-</sup> 60/562,386	11/24/2005	Harding et al.	
	A18	<sup>US-</sup> 60/636,002	11/24/2005	Harding et al.	
	A19	<sup>US-</sup> 6,835,550	12/28/2004	Estell et al.	

			N PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Г
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Topicani o ono balaniani	Or Relevant Figures Appear	To
	B1	EP 0 196 864 A2	10/08/1986	Cetus Corporation		
	B2	WO 00/24782 A2	05/04/2000	Amgen Inc.		
	B3	WO 03/105757 A2	12/24/2003	Genencor International		
	1					1

Examiner Date	
Signature	

\*EXAMINER\* Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and no EXAMPLE: Indian responsible comparison of the control of the contr Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012 OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 9

(Use as many sheets as necessary)

Sheet 2

Co	mplete if Known	,
Application Number	10/581,106	/····
Filing Date	May 31, 2006	
First Named Inventor	Judith A. Fox	
Art Unit	1642	
Examiner Name	Unassigned	
Attorney Docket Number	GC822-US	

				T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f Innoun)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	1	US- 6,903,203	06/07/2005	Copley et al.	
		US-			
	<b>†</b>	US-			
		US-			
	<b>†</b>	US-			
	<b>†</b>	US-			
	1	US-			~
	<b>†</b>	US-			
	<b>†</b>	US-			
	<b>†</b>	US-			
	<b></b>	US-			
	<b>†</b>	US-			
	<b>†</b>	US-		1	
	1	US-			
	T	US-			
	+	US-			

			PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>

1	Examiner	Date	
1	Signature	Considered	
1			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and no "EXAMINET: Initial if reference considered, whether or not diation is in conformance with MPEP 000. Draw line through cation in not in conformance and not considered, which so capt of this Exempt with red commissions to applicate. Applicates usuage clearly calculated unable (options)" Des clear ficts observed. Applications of the conformance of the conf For Translation is attached.

This collection of information is required by 37 CFR 1.67 and 1.66. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gallwring, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the mindvolud case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burner, should be sent to the Chief Information Officer, U.S., Patent and Trademant Office, P.O. 8b. 1459, Alexandria, V.A. 22313-1450. DNOT SEND FEED FORMSTO THE DORRES. SEND TO: Commissioner for Patents, P.O. Box 1459, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are	e required to respond to a collection	of information unless it contains a valid OMB control number.  Complete if Known
	Application Number	10/581,106
INFORMATION DISCLOSURE	Filing Date	May 31, 2006
STATEMENT BY APPLICANT	First Named Inventor	Judith A. Fox
(Use as many sheets as necessary)	Art Unit	1642
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Examiner Name	Unassigned
Sheet 3 of 9	Attorney Docket Number	GC822-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	ALTSCHUL, S.F., et al. "Basic local alignment search tool." J. Mol. Biol., 215(3): 403-410, 1990.	
	C2	ALTSCHUL, S.F., et al. "Gapped BLAST and PSI—BLAST: a new generation of protein database search programs." Nucleic Acids Res., 25(17): 3389—3402, 1997.	
	СЗ	**AUSUBEL, et al., eds., Current Protocols in Molecular Biology, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, 1989.	
	C4	BAGSHAWE, K.D., et al. "Developments with targeted enzymes in cancer therapy." Current Opinion in Immunology 11(5): 579-583, 1999.	
	C5	BEAUCAGE, S.L., et al., "Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis." Tetrahedron Lett., 22(20): 1859-1862, 1981.	
	C6	BENITO, A., et al. "Insertion of a 27 amino acid viral peptide in different zones of Escherichia coli ß galactosidase:" FEMS Microbiology Letters, 123(1-2): 107-112, 1994.	
	C7	BOEHM, M.K., et al. "Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody" Biochemical Journal, 346: 519-528, 2000.	
	C8	BOLIVAR, F., et al. "Construction and characterization of new cloning vehicles. II. A multipurpose cloning system." Gene, 2(2): 95-113, 1977.	
	C9	BROACH, J.R. "Construction of high copy yeast vectors using 2-µm circle sequences." Methods in Enzymology, 101: 307-325, 1983.	
	C10	BROWN, E.L., et al. "Chemical synthesis and cloning of a tyrosine tRNA gene." Methods in Enzymology, 68: 109-151, 1979.	

Signature	Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 60	Oraw line through cital	tion if not in conformance and not

Date

Examiner

<sup>\*</sup>LXAMINEX\*: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Proprietars undergreated to expect the sequence of proceedings of the process of the sequence of the sequence

Approved for use through 07/31/2012. OMB 0951-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/581.106 INFORMATION DISCLOSURE Filing Date May 31, 2006 STATEMENT BY APPLICANT First Named Inventor Judith A. Fox Art Unit 1642 (Use as many sheets as necessary) **Examiner Name** Unassigned Sheet 4 9 Attorney Docket Number GC822-US of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C11	CHANG, A., et al. "Phenotypic expression in E. coli of a DNA sequence coding for mouse dihydrofolate reductase." Nature, 275: 617-624, 1978.	
	C12	CHANG, M., et al. "The roles of indoleglycerol phosphate and the Trpl protein in the expression of trpBA from" Nucleic Acids Research, 18(4): 979-988, 1990.	
	C13	CHRISTOFIDOU-SOLOMIDOU, M., et al. "Immunotargeting of glucose oxidase to endothelium in vivo causes" Am J Physiol Lung Cell Mol Physiol, 278(4): L794-L805, 2000.	
	C14	CLARKE, L., et al. "Selection procedure for isolation of centromere DNAs from Saccharomyces cerevisiae." Methods in Enzymology, 101: 300-307, 1983.	
	C15	CLEWELL, D.B. "Nature of Col E1 Plasmid Replication in Escherichia coli in the Presence of Chloramphenicol." J. Bacteriol., 110(2): 667-676, 1972.	
	C16	CLEWELL, D.B., et al. "Supercoiled circular DNA-protein complex in Escherichia coli: purification and induced" Proc. Natl. Acad. Sci. USA, 62(4): 1159-1166, 1969.	
	C17	COHEN, S.N., et al. "Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia" Proc. Natl. Acad. Sci. USA, 69(8): 2110-2114, 1972.	
	C18	**Cruz, et al., (eds), "Tissue Culture," Academic Press, 1973.	
	C19	DENNY, W.A. "Prodrug strategies in cancer therapy." Eur. J. of Med. Chem., 36 (7-8): 577-595, 2001.	
	C20	DEPICKER, A., et al. "Nopaline synthase: transcript mapping and DNA sequence." Journal of Molecular and Applied Genetics, 1(6): 561-573, 1982.	

- 1		Date
-1	Signature	Considered
•	"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MP	PEP 609 Draw line through citation if not in conformance and not

Date

Examiner

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Consideration include copy or ansorm with next communication to appearant to the payment of the control of the

Approved for use through 07/31/2012. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO			e required to respond to a collection	of information unless it contains a valid OMB control number.  Complete if Known
( Substitu	NE IOI IOIII 1440/FTO			Application Number	10/581,106
3			CLOSURE	Filing Date	May 31, 2006
STATEMENT BY APPLICANT				First Named Inventor	Judith A. Fox
	(Use as many she	afe se n	eressan)	Art Unit	1642
	(ood do many one			Examiner Name	Unassigned
Sheet	5	of	9	Attorney Docket Number	GC822-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), little of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C21	FIERS, W., et al. "Complete nucleotide sequence of SV40 DNA." Nature, 273(5658): 113-120, 1978.	
	C22	FRANCIS, R.J., et al. "A phase 1 trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal" Br. J. Cancer, 87(6): 600-607, 2002.	
	C23	FRANKEL, A., et al. "Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated" Clinical Cancer Research 6(9): 3719-3728, 2000.	
	C24	GOEDDEL, D.V., et al. "Direct expression in Eschericia coli of a DNA sequence coding for human growth hormone." Nature, 281: 544-548, 1979.	
	C25	GOEDDEL, D.V., et al. "Synthesis of human fibroblast interferon by E. coli." Nucl. Acids Res., 8(18): 4057-4074, 1980.	
	C26	GOLD, P., et al. "Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and" J Exp Med., 121(3): 439–462, 1965.	
	, C27	GOODCHILD, J. "Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties." Bioconjug. Chem., 1(3): 165-87, 1990.	
	C28	GRAHAM, F.L., et al. "A new technique for the assay of infectivity of human adenovirus 5 DNA." Virology, 52(2): 456-467, 1973.	
	C29	HESS, B., et al. "Cooperation of glycolytic enzymes." Advances in Enzyme Regulation, 7: 149-167, 1968.	
	C30	HITZEMAN, R.A., et al. *Isolation and characterization of the yeast 3-phosphoglycerokinase gene (PGK) by an immunological* J. Biol. Chem., 255(24): 12073-12080, 1980.	

Signature	Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPF	EP 609 Draw line through citation if not in or	onformance and not

Date

Examiner

considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to appearent.

1 Applicant is unjust extlained designation number (portional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant is unjust extlained designation number (portional). 2 Applicant is to place an obtain or retain a brainfit by the public which is to life (and by the USPTO for control of the public which is to life (and by the USPTO for control of the public which is to life (and by the USPTO for control of the public pub Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it control number:

Substitute for form 1449/PTO	e required to respond to a collection	of information unless it contains a valid OMB control number.  Complete if Known
0.0000000000000000000000000000000000000	Application Number	10/581,106
INFORMATION DISCLOSURE	APPLICANT 10/581,106 ATION DISCLOSURE ENT BY APPLICANT  s many sheets as necessary)  Application Number 10/581,106 Filing Date May 31, 2006 First Named Inventor Judith A. Fox Art Unit 1642 Examiner Name Unassigned  Attempts Desire Number	
STATEMENT BY APPLICANT	First Named Inventor	Judith A. Fox
(Use as many sheets as necessary)	Art Unit	1642
(cos as many street as meetadary)	Application Number 10/581,106  DISCLOSURE Filing Date May 31, 2006  APPLICANT First Named Inventor Judith A. Fox  Art Unit 1642  Examiner Name Unassigned  Anappropriet Number 10/581,106	
Sheet 6 of 9	Attorney Docket Number	GC822-US

F	0.4-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sertal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C31	HOLLAND, M.J., et al. "Isolation and identification of yeast messenger ribonucleic acids coding for enclase" Biochemistry, 17(23): 4900-4907, 1978.	
	C32	HOLLAND, M.J., et al. "The primary structures of two yeast enclase genes. Homology between the 5' noncoding flanking regions" J. Biol. Chem., 256(3): 1385-1395, 1981.	
	C33	HSIAO, CL., et al. "High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene." Proc. Natl. Acad. Sci. USA, 76(8): 3829-3333, 1979.	
	C34	KERR, D.E., et al. "Development and activities of a new melphalan prodrug designed for tumor-selective activation." Bioconjugate Chemistry, 9(2): 255-259, 1998.	
	C35	MARGOLIN, A.L., et al. "Substrate specificity of penicillin amidase from E. coli." Biochim. Biophys. Acta., 616(2): 283-289, 1980.	
	C36	MAXAM, A.M., et al. "Sequencing end-labeled DNA with base-specific chemical cleavages." Methods in Enzymology, 65(1): 499-560, 1980.	
	C37	MCDONAGH, C.F., et al. "Improved Yield and Stability of L49-sFv-β-Lactamase, a Single-Chain Antibody Fusion Protein for" Bioconjugate Chemistry, 14(5): 860-869, 2003.	
	C38	**MELTON, et al., Enzyme-Prodrug Strategies for Cancer Therapy Kluwer Academic/Plenum Publishers, New York, 1999	
	C39	MESSING, J., et al. "A system for shotgun DNA sequencing." Nucl. Acids Res., 9(2): 309-321, January 24, 1981.	
	C40	MILLER, D.W., et al. "An Insect Baculovirus Host-Vector" In Genetic Engineering: Principles and Methods, Setlow et al. (eds.), 8: 277-298; New York: Plenum Press, 1986.	

Signature		Considered		
*EXAMINER: Ini	itial if reference considered, whether or not citation is in conformance with MPEP 60	9. Draw line through o	itation if not in conformance and not	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique clastion designation number (optional). 2 Applicant is to place a chock mark here? English tenguage Translation is attached.
This collection of information is required by 3C PER 1.98. The information is required to obtain or retain a benefit by the public which is to fie and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C. 122 and 37 CPR 1.14. This collection is estimated to take 2 hours to complete, including gallering, preprint, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case of the completed application from to the USPTO. Time will vary depending upon the individual case of the Complete application from the USPTO. The vary depending upon the individual case of the Complete application.
The Complete of the Complete application of the Complete application from the USPTO. The vary depending upon the individual case of the Complete application.
The Complete of the C

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO	90000173	01 01 1000, 110 0010010 01	l concern a respond to a concern	of information unless it contains a valid OMB control number.  Complete if Known
Coodina				Application Number	10/581,106
INF	ORMATION	DIS	CLOSURE	Filing Date	May 31, 2006
STATEMENT BY APPLICANT				First Named Inventor	Judith A. Fox
	(Use as many she	atr ar a		Art Unit	1642
	(Ose as many sire	eta da n	acessary)	Examiner Name	Unassigned
Sheet	7	of	9	Attorney Docket Number	GC822-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C41	NAPOLITANO, E.W., et al. "Glubodies: randomized libraries of glutathione transferase enzymes." Chemistry & Biology, 3(5): 359-367, 1996.	
	C42	NARANG, S.A., et al. "Improved phosphotriester method for the synthesis of gene fragments." Meth. Enzymol., 68: 90-98, 1979.	
	C43	NICULESCU-DUVAZ, I., et al. "Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)." Anti-Cancer Drug Design, 14(6): 517-538, 1999.	
	C44	**SAMBROOK, et al., (eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989.	
	C45	SANGER, F., et al. "DNA Sequencing with Chain-Terminating Inhibitors." Proc. Natl. Acad. Sci. USA, 74(12): 5463-5467, 1977.	
	C46	SHAW, C.H., et al. "A general method for the transfer of cloned genes to plant cells." Gene, 23(3): 315-330, 1983.	
	C47	SHIMATAKE, H., et al. "Purified λ regulatory protein cll positively activates promoters for lysogenic development." Nature ,292(5819): 128-132, 1981.	
	C48	SMITH, J.W., et al. "Protein Loop Grafting to Construct a Variant of Tissue-type Plasminogen Activator That Binds Platelet" J. Biol. Chem., 270(51): 30486-30490, 1995.	
	C49	STELLA, V.J., et al. "Prodrugs: A Chemical Approach to Targeted" In Directed Drug Delivery, Borchardt et al. (eds.), pp. 247-267. Clifton, NJ: Humana Press, 1985.	
	C50	STICKLER, M., et al. "Human population-based identification of CD4+ T-cell peptide epitope determinants." Journal of Immunological Methods, 281(1-2): 95-108, 2003.	

Examiner		Date	
Signature		Considered	
*EXAMINER: In	nitial if reference considered, whether or not citation is in conformance with MPEP 60	9. Oraw line through o	itation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Considered: included upon a resident of segregation number (postored). 2 Applicant is not place a check mark here if English tenguage Translation is stratered.

1. Applicant's unique citation designation number (postored). 2 Applicant is not place a check mark here if English tenguage Translation is stratered.

1. Applicant is unique of the postored in the control of the control of the postored in the postored Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
Substitute for form 11100 p.g.	Application Number	10/581,106	
INFORMATION DISCLOSURE	Filing Date	May 31, 2006	
STATEMENT BY APPLICANT	First Named Inventor	Judith A. Fox	
(Use as many sheets as necessary)	Art Unit	1642	
,	Examiner Name	Unassigned	
Sheet 8 of 9	Application Number 10/581,106  Filling Date May 31, 2006  First Named Inventor Judith A. Fox  Art Unit 1642		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C51	STINCHCOMB, D.T., et al. "Isolation and characterisation of a yeast chromosomal replicator." Nature, 282(5734): 39-43, 1979.	
	C52	THOMSON, K.S., et al. "Version 2000: the new ß-lactamases of Gram-negative bacteria at the dawn of the new millennium." Microbes and Infection, 2(10): 1225-1235, 2000.	
	C53	TORCHILIN, V.P. "Drug targeting." European Journal of Pharmaceutical Sciences, 11(Supplement 2): S81-S91, 2000.	
	C54	TROUET, A., et al. "A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal" Proc. Natl. Acad. Sci. USA, 79(2): 1982.	
	C55	TSCHUMPER, G., et al. "Sequence of a yeast DNA fragment containing a chromosomal replicator and the TRP1 gene." Gene, 10(2): 157-166, 1980.	
	C56	UMEMOTO, N., et al. "Preparation and in vitro cytotoxicity of a methotrexate-anti-MM46 monoclonal antibody conjugate via an" Int J Cancer, 43(4): 677-684, 1989.	
	C57	VAN SOLINGEN, P., et al. "Fusion of yeast spheroplasts." J. Bacteriol., 130(2): 946-947, 1977.	
	C58	VAUGHN, D.E., et al. "Structural basis of pH-dependent antibody binding by the neonatal Fc receptor." Structure, 6(1): 63-73, 1998.	
	C59	WILMAN, D.E., "Prodrugs in cancer chemotherapy." Biochemical Society Transactions 14(2): 375-382, 1986.	
	C60	XU, G., et al. "Strategies for Enzyme/Prodrug Cancer Therapy." Clin. Cancer Res., 7(11): 3314-3324, 2001.	

	Signature	Date	
1		Considered	

considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. \*Appears as unique claimation to sequence (opportune), \*Appearant to pose a content man, mere it engines tanguage ransation is authorized to the content of the content of the property of the public which is to file (and by the USPTO to process) an application. Confidentially is governed by \$5 US, 6.12 and \$7 USPTA.1. This collection is estimated to take 2 hours to complete operations, and submitting the completed application form to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form another suggestions for reducing this bunden, should be sent to the Chief Information Officer, US petent and "Taddemark Office, OS, OS, ot 1450, Assayaring, NZ 2013-1450, DO NOT SEAD FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO			re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
	to to to the to			Application Number	10/581,106	
1			CLOSURE	Filing Date	May 31, 2006	
STATEMENT BY APPLICANT				First Named Inventor	Judith A. Fox	
	(Use as many she	ets as n	ecessary)	Art Unit	1642	
lose as many should be necessary				Examiner Name	Unassigned	
Sheet	9	of	9	Attorney Docket Number	GC822-US	

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
-	C61	European Search Report (Supplemental) – EP 04813700.4 – PCT/US2004041429 dated February 11, 2008.	
•			

Examiner	Date	
Signature	Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 60	<ol> <li>Draw line through o</li> </ol>	itation if not in conformance and not
considered. Include copy of this form with next communication to applicant.		

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Considered: include copy or insignment with next communication or appearant.

Applicant as unique clation designation number (gottom). 2 Applicant is not pade a choice mark here if English language Translation is attached.

1 Applicant as unique clation designation number (gottom). 2 Applicant is to pade a choice mark here if English language Translation is attached.

1 to process an application. Confidentially is governed by 35 U.S.C. 152 and 37 CPR 1.14. This collection is estimated to bits 2 hours to complete, including pathering, preparing, and submitting the completed application from the full SMFTO. Time will keep very depending upon the individual case of processing and processing the completed application from the full SMFTO. Time will keep very depending upon the individual case of the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademank. Office, P.O. Dos. 1450. Avandrial, N. 2023-1436. D. NOT SEND FEES DR COMPLETED FORMS TO THIS ADDRESS. SEND TO: